Manuel Modiano - Concepedia

Author

Manuel Modiano

Also Known As

Laura Maria Fogliatto, M Modiano, M R Modiano, M. Modiano, M. R. MODIANO, M. R. Modiano, M.R Modiano, M.R. Modiano, MANUEL MODIANO, MANUEL R. MODIANO

124

Publications

10.4K

Citations

H-Index

Concepts

All Affiliations

Arizona Research Center Arizona Oncology University of Arizona Sarah Cannon The University of Texas MD Anderson Cancer Center

About

Manuel Modiano is an author at Arizona Research Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	31	1.5K
2	Health Sciences	10	10	402
3	Nursing	2	2	123
4	Public Health	2	2	123
5	Diagnostic Sciences	1	1	166

Manuel Modiano

Publications

10.2K

Citations

H-Index

Page 1

	Year	Citations
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, Journal of Clinical Oncology	1997	5.8K
Adjuvant Docetaxel for Node-Positive Breast Cancer Miguel Martín, Tadeusz Pieńkowski, John R. Mackey, New England Journal of Medicine	2005	950
Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic Cancer Ghassan K. Abou‐Alfa, Richard Létourneau, Graydon Harker, Journal of Clinical Oncology	2006	277
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial John R. Mackey, Miguel Martín, Tadeusz Pieńkowski, The Lancet Oncology Node-positive Breast CancerBreast OncologyOncologyAdjuvant DocetaxelBcirg 001	2012	221
PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer Ralph Zinner, Coleman K. Obasaju, David R. Spigel, Journal of Thoracic Oncology	2014	171
Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer William R. Berry, Shaker R. Dakhil, Manuel Modiano, The Journal of Urology Median TimePharmacotherapyGynecology OncologyOncologyGenitourinary Cancer	2002	166
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, Journal of Clinical Oncology	2023	165
Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. William R. Berry, Shaker R. Dakhil, Manuel Modiano, PubMed	2002	158
Randomized Phase I Trial of Recombinant Human Keratinocyte Growth Factor Plus Chemotherapy: Potential Role as Mucosal Protectant Neal J. Meropol, Robert A. Somer, John Gutheil, Journal of Clinical Oncology	2003	151
Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial Lee S. Schwartzberg, Manuel Modiano, Bernardo L. Rapoport, The Lancet Oncology Emetogenic ChemotherapyOncologyCyclophosphamide RegimensChemotherapy-induced NauseaGastrointestinal Oncology	2015	149

Page 1